TransEnterix, Inc. (NYSEAMERICAN:TRXC) was the target of a large increase in short interest during the month of March. As of March 29th, there was short interest totalling 38,726,892 shares, an increase of 0.0% from the March 15th total of 38,711,341 shares. Based on an average trading volume of 2,361,986 shares, the short-interest ratio is currently 16.4 days. Approximately 21.6% of the company’s shares are short sold.

Separately, Zacks Investment Research lowered shares of TransEnterix from a “buy” rating to a “hold” rating in a research note on Friday, January 11th.

In other TransEnterix news, CFO Joseph P. Slattery sold 88,871 shares of the firm’s stock in a transaction on Friday, February 22nd. The shares were sold at an average price of $3.25, for a total value of $288,830.75. Following the sale, the chief financial officer now owns 44,929 shares of the company’s stock, valued at approximately $146,019.25. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Institutional investors and hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of TransEnterix during the 4th quarter valued at about $29,000. Cetera Advisors LLC bought a new stake in shares of TransEnterix during the 4th quarter valued at about $34,000. B. Riley Wealth Management Inc. bought a new stake in shares of TransEnterix during the 3rd quarter valued at about $90,000. Oppenheimer & Co. Inc. lifted its position in TransEnterix by 105.6% during the 4th quarter. Oppenheimer & Co. Inc. now owns 22,000 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 11,300 shares during the period. Finally, Amalgamated Bank purchased a new position in TransEnterix during the 4th quarter valued at about $54,000.

Shares of TRXC opened at $2.50 on Thursday. TransEnterix has a 1-year low of $1.65 and a 1-year high of $6.98.

TransEnterix (NYSEAMERICAN:TRXC) last announced its earnings results on Tuesday, February 26th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). The firm had revenue of $7.50 million for the quarter, compared to analysts’ expectations of $7.35 million. The business’s revenue for the quarter was up 120.6% on a year-over-year basis.

ILLEGAL ACTIVITY NOTICE: “TransEnterix, Inc. (TRXC) Short Interest Up 0.0% in March” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at

About TransEnterix

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

Read More: Strangles

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with's FREE daily email newsletter.